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Introduction
While there has been an undeniable acceleration of 
advances in thoracic oncology in the fields of surgery, 
radiation oncology, and medical oncology, coordination 
and tailored selection of treatment modalities has become 
increasingly complex. As more therapeutic options become 
available, the standard-of-care for early stage, locally 
advanced, and metastatic lung, esophageal, and pleural 
malignancies is continually evolving. This ongoing state 
of change requires the development of robust, multi-
disciplinary care approaches to facilitate effective, often 
individually tailored, treatment plans. 
While increasing complexity in both disease presentation 
and therapeutic options mandate multidisciplinary input, 
time pressures on clinicians required to provide such 
care have also increased (1). Hence, it is imperative to 
ensure that these processes are as effective and efficient as 
possible. Complex, multidisciplinary oncology care—like 
that required for the treatment of thoracic malignancies is 
an area in which quality of care has yet to be purposefully 
def ined and thoroughly  measured.  Per formance 
measurement is a burgeoning area within healthcare in 
general, but implementing measurement principles in this 
domain is a particular challenge because much of thoracic 
oncology care requires precise coordination of complex 
care from multiple specialties and which spans the range 
of curative to palliative care. Here, we discuss the role 
of multi-disciplinary thoracic oncologic care, metrics of 
quality, and future directions. 
What is multidisciplinary care?
Multidisciplinary care is commonly understood to represent 
a model of healthcare delivery which is comprised of 
coordinated care delivered by groups of appropriate 
specialists. Multidisciplinary teams in thoracic malignancies, 
typically include thoracic surgeons, radiation oncologists, 
pathologists, thoracic radiologists, medical oncologists, 
and palliative care specialists. This paradigm of care is 
Review Article
Measuring the quality of multi-disciplinary thoracic oncology care
Elliot Wakeam1, David Odell2,3, Pamela Samson4 
1Division of Thoracic Surgery, Toronto General Hospital, University of Toronto, Toronto, ON, Canada; 2Division of Thoracic Surgery, 3Surgical 
Outcomes and Quality Improvement Center, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine. 
Chicago, IL, USA; 4Department of Radiation Oncology, Washington University in St. Louis, St. Louis, MO, USA
Contributions: (I) Conception and design: E Wakeam, P Samson; (II) Administrative support: None; (III) Provision of study materials or patients: 
None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final 
approval of manuscript: All authors.
Correspondence to: Elliot Wakeam, MD, MPH. Toronto General Hospital, 200 Elizabeth Street, Toronto, ON, Canada. Email: Eliot.wakeam@uhn.ca.
Abstract: As a result of the rapid acceleration in new treatment advances in thoracic oncology, 
coordination and tailored selection of treatment modalities has become complex. This increasing complexity 
mandates multidisciplinary input and coordinated management. However, quality of care in the domain 
of multidisciplinary thoracic oncology has yet to be purposefully defined, and as a result the science of 
performance measurement has yet to be applied to this area. In this review we discuss the role of multi-
disciplinary care in thoracic oncology, and outline its definitions as proposed in the literature. We review 
various metrics of quality in complex multidisciplinary thoracic oncology care, and future directions for 
quality and performance measurement. 
Keywords: Multidisciplinary care; oncology; quality measurement; tumor board
Submitted Nov 08, 2018. Accepted for publication Feb 25, 2019.
doi: 10.21037/jtd.2019.02.72
View this article at: http://dx.doi.org/10.21037/jtd.2019.02.72
565
S563Journal of Thoracic Disease, Vol 11, Suppl 4 March 2019
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2019;11(Suppl 4):S562-S565jtd.amegroups.com
widely advocated by professional groups and supported in 
clinical guidelines (2). Similarly, patient advocacy efforts 
also frequently focus on promoting multidisciplinary 
care as a counterweight to the variability and uncertainty 
in care decisions often encountered by patients. This is 
especially true for those patients with rare cancers such as 
advanced thymoma or mesothelioma. However, the discrete 
operational characteristics of multidisciplinary care delivery 
are only vaguely described in the literature. 
The classic example of multidisciplinary care is the 
tumor board meeting, in which physicians of representative 
specialties discuss cases requiring complex management. 
Typically, cases are presented and a consensus management 
plan arrived upon as a result of the discussion by the 
physicians in attendance. The value of these groups has 
been most discretely measured in terms of changes made 
to patient diagnostic or therapeutic management plans (3). 
While these tumor boards certainly do add value in 
these tangible domains, they may also aid in clinical trial 
consideration and recruitment (4). This is not necessarily 
limited to the academic environment, as community 
hospital tumor boards frequently serve as the mechanism to 
facilitate referral to tertiary or quaternary care centers. 
Defining the quality of multidisciplinary care
Defining quality in complex thoracic oncology care is an 
open question. What, precisely, does quality care look 
like, and from whose perspective? For the purposes of this 
article, we will focus on specific measurement strategies 
and techniques for performance measurement that may 
be applicable to the measurement of the care delivered by 
teams treating patients with thoracic malignancy.
T h e  f i r s t  t a s k  i n  m e a s u r i n g  t h e  q u a l i t y  o f 
multidisciplinary care is to define it. Osarogiagbon 
proposes 4 key factors that must be present to meet the 
definition of multidisciplinary care: the clinical interaction 
must be prospective, so that opportunity remains for the 
interdisciplinary engagement to influence the care and 
outcomes of the individual patient; key members of the 
thoracic oncology care delivery team must be engaged; 
accurate data must be presented and reviewed; and a robust 
framework for communication must be established (2,5).
With these 4 key factors defined, the structure of the 
actual care delivery environment can vary based upon 
the local context in which care is delivered. For example, 
whether clinicians of various specialties interact with 
patients in a co-located clinic, by conference without direct 
patient involvement, or virtually, is less important. Granular 
aspects of the function of the multidisciplinary team 
(MDT) can then be measured—for example, measurement 
of tumor board performance via a basic checklist to 
ensure that essential personnel are present and the critical 
elements of the history, pathology and radiology studies 
are available for review. The incorporation of all relevant 
patient information in the MDT discussion is a particular 
strength of this multidisciplinary approach to care, 
allowing for individualization of treatment decisions. For 
example, the presence of comorbid conditions frequently 
influences treatment recommendations (6). Hence, accurate 
information regarding all aspects of the patient’s medical 
history, not merely focused information regarding the 
oncologic problem are necessary for the MDT to make 
appropriate treatment recommendations. 
Measuring quality
With the framework of multidisciplinary care defined, the 
focus next shifts to determining how to measure the quality 
and performance of these functional units. Benchmarking, 
whereby multidisciplinary units of similar constitution 
and function are compared, has yet to be applied to the 
assessment of multi-disciplinary care. Single specialty efforts 
to benchmark outcomes, by contrast, are well developed in 
thoracic surgery, especially for short-term surgical outcomes 
such as 30-day mortality (7). 
Efforts to directly measure multi-disciplinary care have 
to this point been lacking. Most studies of the process 
and outcomes effects of multidisciplinary care have 
been retrospective; either non-comparative or pre-post 
intervention studies. Process outcomes, such as timeliness 
of care, or utilization of appropriate staging modalities, have 
dominated ‘hard’ outcomes such as survival, presumably 
due to their relative ease of capture and short-term 
measurement in retrospective data. Further, some authors 
question the applicability of survival as an appropriate 
outcome, especially for palliative patient populations. 
Studies of tumor boards, by contrast, have focused on their 
impact in increasing utilization of guideline concordant 
care (3,6,8-10). Indeed, the proportion of treatment 
decision changes made as a result of multidisciplinary 
review has been proposed as a quality metric. Vinod and 
colleagues found that guideline concordance with respect 
to the recommendations concerning surgery, radiation 
and chemotherapy only approached 70% on average, with 
recommendations for surgery where guidelines would 
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recommend it in only 60% of examined cases. Deviations 
largely arose as a result of advanced patient age, comorbidity 
and performance status (9). Patient-centered outcomes, which 
are as important, if not more so in patients with cancer, are 
also largely unstudied in thoracic oncology. One preliminary 
qualitative study has shown high satisfaction with clinic 
co-location of services for lung cancer patients (11).
One approach to analyzing and measuring the quality 
of multi-disciplinary thoracic oncology care is to break 
the care elements down into the specialty blocks which 
comprise the care team. For example, surgical resection 
rates for early stage disease, or the proportion of patients 
undergoing lymph node staging have been suggested as 
possible endpoints (2). While a great deal of progress 
has been made in the measurement of surgical quality in 
isolation, measurement of quality in other domains of 
thoracic oncology, such as radiation, medical oncology and 
palliative care are less well defined. Even within specialties 
such as surgery where outcomes and quality have been 
studied extensively, they have largely been limited to broad 
perioperative domains such as mortality, complications 
and readmissions (7). While certainly more feasible, 
measuring the quality of one domain in isolation gives 
a narrow picture of the breadth of care that is provided 
by multidisciplinary teams. Far more complex is the 
measurement of the interaction between specialists and 
the function of multidisciplinary cancer conferences in 
assuring guideline-concordant and high quality care (3). 
Some initial attempts to measure these interactions have 
demonstrated potentially meaningful gaps in quality. 
Rajaram and colleagues found significant underutilization 
of adjuvant chemotherapy following surgical resection in 
a national study (12). Credentialing groups such as the 
Commission on Cancer have incorporated quality measures 
into the review paradigm for programs, but the areas that 
perform most poorly related to the transition of care from 
one specialist to another (13). These interactions are what we 
believe provide for the best care in complex cases, and yet their 
outcomes remain nebulous. Overall survival seems an obvious 
starting point, but even then, it only applies to the fraction of 
patients treated curatively and misses a large proportion of care 
provided by all specialties dealing with thoracic cancers, many 
of which are done within a palliative framework. 
Future directions of multidisciplinary care
While the landscape of multidisciplinary care has certainly 
evolved in the last decade, the current era in thoracic 
oncology demands perhaps the greatest level of integration. 
The advent of immunotherapy, improvements in radiation 
techniques, and developments in the safety and efficacy of 
surgery have thrown into question traditional treatment 
paradigms and created many areas of uncertainty. 
Virtual tumor boards may aid in extending the benefits 
of multidisciplinary care for these situations to patients 
in remote areas (14), while “mini tumor boards” have 
been proposed for patients in low- and middle-income 
countries (10). Clearly, patient-centered outcomes such as 
quality of life and satisfaction are an area in need of greater 
attention and research, and what impact multidisciplinary 
care has on these important measures of healthcare 
efficiency and efficacy must be investigated. Demonstrating 
the utility of multidisciplinary care in terms of increased 
efficiency, or timeliness of care, may help to motivate the 
uptake of the multidisciplinary approaches, building on 
the work of Osarogiagbon and colleagues, particularly 
for the idea of co-located clinics (2). One of the main 
questions that future studies will need to answer is the 
relative effectiveness of clinic co-location, which has the 
advantage of multidisciplinary input while the patient is 
being evaluated, versus organ-specific tumor boards which 
occur after the individual evaluations have taken place. 
Lastly, while these tumor boards are clearly important on 
an individual level, the impact of multi-disciplinary models 
on a population-level has not been evaluated, but is likely 
significant. Measuring the benefits of these approaches, 
while challenging, is key to engaging clinicians in a way that 
is relevant to their clinical practice. 
Conclusions 
In an era of rapid changes in thoracic oncology, clinician 
engagement in multidisciplinary care is more important 
than ever. Although the concept of measuring the function 
of multidisciplinary groups is intrinsically appealing, 
the definition, structure and relevant outcomes for such 
groups remain largely undefined. Despite the challenges, 
however, progress is being made especially with respect to 
the development of relevant patient-centered outcomes, 
which are critical for the measurement of care quality 
in the majority of advanced staged lung cancer patients. 
While measurement of impact remains a challenge, 
multidisciplinary care represents a platform for quality 
improvement and knowledge translation that is more 
critical than ever in the complex and evolving field of 
thoracic oncology.
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